Literature DB >> 17376833

The use of idd congenic mice to identify checkpoints of peripheral tolerance to islet antigen.

Emma E Hamilton-Williams1, Xavier Martinez, Michael Lyman, Kara Hunter, Linda S Wicker, Linda A Sherman.   

Abstract

Type 1 diabetes (T1D) occurs because of lack of T cell tolerance to islet antigens. We hypothesized that critical genetic susceptibility loci that control progression to T1D, designated as insulin-dependent diabetes (Idd) loci, would be responsible for preventing CD8 T cell tolerance. To test this hypothesis, we have used two different congenic non-obese diabetic (NOD) mice that are highly protected from the occurrence of T1D because they express protective alleles at Idd3 and Idd5.1, 5.2, 5.3 (Idd3/5 mice), or at Idd9.1, 9.2, and 9.3 (Idd9 mice). By examining the CD8 T response to two different islet-expressed antigens, we have determined that CD8 T tolerance is restored in both strains of mice. However, tolerance occurs at different checkpoints in each strain. In Idd3/5 mice, islet-antigen-specific CD8 T cells are eliminated in the pancreatic lymph nodes, where they are first activated by cross-presented islet antigens. In contrast, in Idd9 mice autoreactive CD8 T cells accumulate at this site and are not tolerized until after they enter the pancreas. We are currently identifying the cell types and mechanisms that are critical for tolerance induction at each checkpoint.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17376833     DOI: 10.1196/annals.1394.003

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  7 in total

1.  Expression of diabetes-associated genes by dendritic cells and CD4 T cells drives the loss of tolerance in nonobese diabetic mice.

Authors:  Emma E Hamilton-Williams; Xavier Martinez; Jan Clark; Sarah Howlett; Kara M Hunter; Daniel B Rainbow; Li Wen; Mark J Shlomchik; Jonathan D Katz; Georg F Beilhack; Linda S Wicker; Linda A Sherman
Journal:  J Immunol       Date:  2009-07-10       Impact factor: 5.422

2.  Genetic interactions among Idd3, Idd5.1, Idd5.2, and Idd5.3 protective loci in the nonobese diabetic mouse model of type 1 diabetes.

Authors:  Xiaotian Lin; Emma E Hamilton-Williams; Daniel B Rainbow; Kara M Hunter; Yang D Dai; Jocelyn Cheung; Laurence B Peterson; Linda S Wicker; Linda A Sherman
Journal:  J Immunol       Date:  2013-02-20       Impact factor: 5.422

3.  Idd9.2 and Idd9.3 protective alleles function in CD4+ T-cells and nonlymphoid cells to prevent expansion of pathogenic islet-specific CD8+ T-cells.

Authors:  Emma E Hamilton-Williams; S B Justin Wong; Xavier Martinez; Daniel B Rainbow; Kara M Hunter; Linda S Wicker; Linda A Sherman
Journal:  Diabetes       Date:  2010-03-18       Impact factor: 9.461

4.  Cellular mechanisms of restored β-cell tolerance mediated by protective alleles of Idd3 and Idd5.

Authors:  Emma E Hamilton-Williams; Jocelyn Cheung; Daniel B Rainbow; Kara M Hunter; Linda S Wicker; Linda A Sherman
Journal:  Diabetes       Date:  2011-11-21       Impact factor: 9.461

5.  Distinct genetic control of autoimmune neuropathy and diabetes in the non-obese diabetic background.

Authors:  Hélène Bour-Jordan; Heather L Thompson; Jennifer R Giampaolo; Dan Davini; Wendy Rosenthal; Jeffrey A Bluestone
Journal:  J Autoimmun       Date:  2013-07-12       Impact factor: 7.094

6.  Idd9.1 locus controls the suppressive activity of FoxP3+CD4+CD25+ regulatory T-cells.

Authors:  Jun Yamanouchi; Maria-Carmen Puertas; Joan Verdaguer; Paul A Lyons; Daniel B Rainbow; Giselle Chamberlain; Kara M Hunter; Laurence B Peterson; Linda S Wicker; Pere Santamaria
Journal:  Diabetes       Date:  2009-10-15       Impact factor: 9.461

7.  Fine mapping of type 1 diabetes regions Idd9.1 and Idd9.2 reveals genetic complexity.

Authors:  Emma E Hamilton-Williams; Daniel B Rainbow; Jocelyn Cheung; Mikkel Christensen; Paul A Lyons; Laurence B Peterson; Charles A Steward; Linda A Sherman; Linda S Wicker
Journal:  Mamm Genome       Date:  2013-08-11       Impact factor: 2.957

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.